Clinical Trials Browser

Phase 2 × Trastuzumab × Gastrointestinal × Clear all

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05515796 2026-04-01

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Phase 2 Completed

Gastrointestinal

Rectal Neoplasms, Stomach Neoplasms

NCT06178445 2026-03-27

TRAP-BTC

Phase 2 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

240 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

Gastrointestinal

Colonic Neoplasms

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06468280 2026-01-21

ROSETTE

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2 Active not recruiting

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT02205047 2025-07-31

INNOVATION

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT02678182 2025-06-10

PLATFORM

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06589830 2025-05-15

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2 Completed

117 enrolled 21 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05715931 2024-09-19

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma of the Stomach

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

Phase 2 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT02291289 2024-05-06

MODUL

Phase 2 Completed

1,044 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03950271 2024-02-28

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03783936 2023-12-19

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Phase 2 Completed

18 enrolled 16 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis

NCT06121700 2023-11-08

Miracle-G

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05997524 2023-08-18

Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.

Phase 2 Completed

Gastrointestinal

Advanced Gastric Carcinoma

NCT04819971 2023-04-25

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02954536 2023-03-16

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Phase 2 Completed

37 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04510285 2023-02-01

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Phase 2 Terminated

1 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT04168931 2023-01-17

GASTHER2

Phase 2 Terminated

Gastrointestinal

Neoplastic Cells, Circulating, Stomach Neoplasms

NCT02725424 2022-08-17

MATCH

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT05170256 2022-08-12

HERES

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05218148 2022-04-06

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Phase 2 Unknown

GastrointestinalOther solid neoplasm

HER2-positive

NCT05311189 2022-04-05

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Phase 2 Unknown

Gastrointestinal

HER2-positive Gastric Cancer

NCT03457896 2022-03-31

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05193292 2022-01-14

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Intestinal Neoplasms, Colorectal Neoplasms

NCT04380012 2021-07-15

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04960943 2021-07-14

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Phase 2 Unknown

Gastrointestinal

Digestive System Neoplasms

NCT01359397 2021-01-27

B-DOCT

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT03613168 2021-01-05

BILHER

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT01402401 2020-12-10

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT01928290 2020-08-25

FOLFIRINOX

Phase 2 Completed

67 enrolled 14 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms